US 2026/0232840 A1Published application

Antibodies and ubiquitin ligase fusion proteins for misfolded superoxide dismutase-1 (sod1)

AssigneesThe University of British Columbia, ProMIS Neurosciences Inc.

InventorsNeil R. CASHMAN, Justin J. YERBURY, Christen G. CHISHOLM

Life of this patent

Estimating the term…

Abstract

Antibody or binding fragment thereof, fusion protein, or pharmaceutical composition directed against misfolded SOD1 epitope, or nucleic acid encoding the antibody or binding fragment thereof, fusion protein, or pharmaceutical composition, are described. Also provided are methods for using and manufacturing such antibody or binding fragment thereof, fusion protein, nucleic acid, or pharmaceutical composition, as well as methods of their use for treating a disorder in a human subject in need thereof.

Claims25

Dependent claims

An isolated antibody or binding fragment thereof that binds to misfolded superoxide dismutase 1 (SOD1) epitope having an amino acid sequence shown in SEQ ID NO:

144, the antibody or binding fragment thereof comprises:
(i) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
1, SEQ ID NO:
2, and SEQ ID NO:
3, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
4, SEQ ID NO:
5, and SEQ ID NO:
6;
(ii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
7, SEQ ID NO:
8, and SEQ ID NO:
9, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11 and SEQ ID NO:
12;
(iii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
14, SEQ ID NO:
15, and SEQ ID NO:
16, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11, and SEQ ID NO:
12;
(iv) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
7, SEQ ID NO:
8, and SEQ ID NO:
9, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11 and SEQ ID NO:
13;
(v) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
14, SEQ ID NO:
15, and SEQ ID NO:
16, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11, and SEQ ID NO:
13;
(vi) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
53, SEQ ID NO:
54, and SEQ ID NO:
55, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
56, SEQ ID NO:
57, and SEQ ID NO:
58;
(vii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
23, SEQ ID NO:
24, and SEQ ID NO:
25, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
26, SEQ ID NO:
27, and SEQ ID NO:
28;
or
(viii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
29, SEQ ID NO:
30, and SEQ ID NO:
31, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
32, SEQ ID NO:
33, and SEQ ID NO:
34.

55 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/157,620Filed 19 Feb 2024
Priority: 17 Feb 2023
Published: 13 Aug 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…
A61K 47/6815
The drug being a protein or peptide, e.g. transferrin or bleomycin: enzymes
A61K 47/6871
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting an enzyme
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…

Family

Application63/446,485Us provisional application · filed 17 Feb 2023
US 2026/0232840 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An isolated antibody or binding fragment thereof that binds to misfolded superoxide dismutase 1 (SOD1) epitope having an amino acid sequence shown in SEQ ID NO:

144, the antibody or binding fragment thereof comprises:
(i) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
1, SEQ ID NO:
2, and SEQ ID NO:
3, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
4, SEQ ID NO:
5, and SEQ ID NO:
6;
(ii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
7, SEQ ID NO:
8, and SEQ ID NO:
9, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11 and SEQ ID NO:
12;
(iii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
14, SEQ ID NO:
15, and SEQ ID NO:
16, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11, and SEQ ID NO:
12;
(iv) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2, and CDR3 having the amino acid sequence of SEQ ID NO:
7, SEQ ID NO:
8, and SEQ ID NO:
9, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11 and SEQ ID NO:
13;
(v) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
14, SEQ ID NO:
15, and SEQ ID NO:
16, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
10, SEQ ID NO:
11, and SEQ ID NO:
13;
(vi) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
53, SEQ ID NO:
54, and SEQ ID NO:
55, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
56, SEQ ID NO:
57, and SEQ ID NO:
58;
(vii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
23, SEQ ID NO:
24, and SEQ ID NO:
25, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
26, SEQ ID NO:
27, and SEQ ID NO:
28;
or
(viii) a heavy chain comprising a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
29, SEQ ID NO:
30, and SEQ ID NO:
31, and a light chain comprising a light chain variable region, wherein the light chain variable region comprises CDR1, CDR2 and CDR3 having the amino acid sequence of SEQ ID NO:
32, SEQ ID NO:
33, and SEQ ID NO:
34.

55 more elements

Facts

Application

19/157,620Filed 19 Feb 2024

Priority

17 Feb 2023

Published

13 Aug 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…
A61K 47/6815
The drug being a protein or peptide, e.g. transferrin or bleomycin: enzymes
A61K 47/6871
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting an enzyme
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…